Choose Your Country or Region

VGX-1027

Name: VGX-1027
Brand: Selleck Chemicals
SKU: S7515
Rating: 5 (1 reviews)

Synonyms: GIT 27

Catalog No.S7515 Purity:99.92%

VGX-1027 (GIT 27) is an orally active immunomodulator. Phase 1.

VGX-1027 Chemical Structure

CAS No. 6501-72-0

Purity & Quality Control

Batch: S751501 DMSO]41 mg/mL]false]Ethanol]41 mg/mL]false]Water]Insoluble]false Purity: 99.92%

99.92

VGX-1027 Related Products

Related Products	Cl-amidine TAPI-1 Bindarit Tempol Anti-mouse CD8α-InVivo Tranilast Sinomenine Geniposidic acid GI254023X CORM-3 Bestatin (Ubenimex) ATP Acacetin Germacrone Oxymatrine Gastrodin Atractylenolide I Y-320 Sinomenine hydrochloride Tomatidine Hydrochloride Thymoquinone Demethylzeylasteral (T-96) Lupeol Flufenamic acid Quercitrin Laquinimod Iguratimod Calycosin Sanguinarine Punicalagin Z-Guggulsterone Fenamic acid Tiragolumab (anti-TIGIT) Geniposide Thymol Jujuboside A PMX-53 6-Shogaol Isoliensinine Tiaprofenic acid Arachidonic acid Astragalin Linarin Isoliquiritin Coumarin Platycodin D Pipecolic acid Umbelliferone Thymopentin Salvianolic acid A Sinigrin Isovitexin Buddlejasaponin IVb Lysionotin Liensinine Ginsenoside CK Lentinan Wogonoside Bakuchiol Carnosol Madecassic acid Acetylharpagide Anwuligan Ginkgetin Eicosapentaenoic Acid (EPA) Tryptanthrin Pranlukast	Click to Expand
Related Compound Libraries	Kinase Inhibitor Library FDA-approved Drug Library Natural Product Library Bioactive Compound Library-I Bioactive Compound Library-Ⅱ	Click to Expand

Biological Activity

Description	VGX-1027 (GIT 27) is an orally active immunomodulator. Phase 1.

In vitro
In vitro	VGX-1027 significantly inhibits both IL-1β/IFN-γ-induced TNF-α and nitrite accumulation, and causes a significant increase in cell survival by interfering with the cytotoxic effects of the cytokines. ^[1] VGX-1027 inhibits both proliferation of enterobacterial antigen-reactive CD4+CD25− T cells in vitro. ^[2]

In Vivo
In vivo	VGX-1027 prevents development of spontaneous type 1 diabetes in NOD Mice and counteracts accelerated diabetogenesis induced by cyclophosphamide challenge or adoptive transfer of diabetogenic spleen cells in NOD Mice. VGX-1027 also reduces clinical signs of MLD-STZ-induced diabetes and suppresses pathohistological changes of pancreas. ^[1] VGX-1027 suppresses the development of clinical, histological and immunological signs of DNBS-induced colitis in CD1 mice. ^[2] In NZB/NZW F1 model of systemic lupus erythematosus (SLE), VGX-1027 ameliorates the course of the disease with higher percent survival and improved clinical and histopathological signs. ^[3]
Animal Research	Animal Models	NOD Mice with MLD-STZ-induced diabetes.
	Dosages	20 mg/kg b.wt. i.p. and 100 mg/kg b.wt. p.o.
	Administration	i.p. or p.o.

References

Chemical Information & Solubility

Molecular Weight	205.21	Formula	C₁₁H₁₁NO₃
CAS No.	6501-72-0	SDF	Download VGX-1027 SDF
Smiles	C1C(ON=C1C2=CC=CC=C2)CC(=O)O
Storage (From the date of receipt)	3 years-20°Cpowder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
Storage (From the date of receipt)	3 years-20°Cpowder		1 month-20°Cin solvent

In vitro
Batch:

DMSO : 41 mg/mL ( (199.79 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 41 mg/mL

Water : Insoluble

Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.

In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):